PAR 4.17% 23.0¢ paradigm biopharmaceuticals limited..

Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-21

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 360 Posts.
    lightbulb Created with Sketch. 42
    Hindsight is the proverbial you know what....but hey i guess you're perfect and have never experienced that feeling before.

    Biotech is hard, i mean really hard. I know as I work in this industry. Things take time, exorbitant amounts of money but more importantly ridiculous amounts of patience. Ethics approvals especially for multicentre projects can be complex and requires finesse as each hospital/clinical site has different levels of governance. There is also the time taken to develop collaborations and relationships with the clinical team to do the trial at a new centre.

    Its a good step forward that a second site has come on board. Lets hope more will come online as the australia P3 trial is commenced.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
23.0¢
Change
-0.010(4.17%)
Mkt cap ! $83.98M
Open High Low Value Volume
25.0¢ 25.0¢ 23.0¢ $59.71K 249.3K

Buyers (Bids)

No. Vol. Price($)
3 438884 23.0¢
 

Sellers (Offers)

Price($) Vol. No.
24.0¢ 36154 3
View Market Depth
Last trade - 10.26am 18/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.